VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | ASC2ESCALATE: dose escalation study of asciminib in second-line CP-CML

Jorge Cortes, MD, Augusta University, Augusta, GA, explains the rationale for the ASC2ESCALATE trial (NCT05384587), which aims to determine whether it is possible to escalate the dosing of asciminib from 80 mg to 200 mg twice daily in patients with chronic myeloid leukemia in the chronic phase (CP-CML) who have not achieved their goal of response at the 12 months. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter